1. Home
  2. ADAP vs ELUT Comparison

ADAP vs ELUT Comparison

Compare ADAP & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAP
  • ELUT
  • Stock Information
  • Founded
  • ADAP 2008
  • ELUT 2015
  • Country
  • ADAP United Kingdom
  • ELUT United States
  • Employees
  • ADAP N/A
  • ELUT N/A
  • Industry
  • ADAP Biotechnology: Pharmaceutical Preparations
  • ELUT Medical Specialities
  • Sector
  • ADAP Health Care
  • ELUT Health Care
  • Exchange
  • ADAP Nasdaq
  • ELUT Nasdaq
  • Market Cap
  • ADAP 75.5M
  • ELUT 71.5M
  • IPO Year
  • ADAP 2015
  • ELUT 2020
  • Fundamental
  • Price
  • ADAP $0.27
  • ELUT $2.38
  • Analyst Decision
  • ADAP Buy
  • ELUT Strong Buy
  • Analyst Count
  • ADAP 6
  • ELUT 2
  • Target Price
  • ADAP $1.35
  • ELUT $8.00
  • AVG Volume (30 Days)
  • ADAP 644.7K
  • ELUT 26.4K
  • Earning Date
  • ADAP 08-11-2025
  • ELUT 08-06-2025
  • Dividend Yield
  • ADAP N/A
  • ELUT N/A
  • EPS Growth
  • ADAP N/A
  • ELUT N/A
  • EPS
  • ADAP N/A
  • ELUT N/A
  • Revenue
  • ADAP $179,639,000.00
  • ELUT $23,711,000.00
  • Revenue This Year
  • ADAP N/A
  • ELUT $20.10
  • Revenue Next Year
  • ADAP $35.48
  • ELUT $85.89
  • P/E Ratio
  • ADAP N/A
  • ELUT N/A
  • Revenue Growth
  • ADAP 878.53
  • ELUT N/A
  • 52 Week Low
  • ADAP $0.20
  • ELUT $1.61
  • 52 Week High
  • ADAP $1.48
  • ELUT $5.12
  • Technical
  • Relative Strength Index (RSI)
  • ADAP 56.59
  • ELUT 69.40
  • Support Level
  • ADAP $0.23
  • ELUT $2.08
  • Resistance Level
  • ADAP $0.28
  • ELUT $2.23
  • Average True Range (ATR)
  • ADAP 0.02
  • ELUT 0.19
  • MACD
  • ADAP 0.00
  • ELUT 0.07
  • Stochastic Oscillator
  • ADAP 87.96
  • ELUT 81.52

About ADAP Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Share on Social Networks: